"Periodic screening and monitoring of CBC while on treatment is crucial to monitor development of neutropenia which can be totally asymptomatic," the authors concluded.
An interaction check showed that norepinephrine is not compatible with insulin in the same line as it renders the insulin ineffective.
Switching basal insulins to GLA-300 vs. other basal insulins showed similarly improved glycemic cotrol but with significantly lower risk of hypoglycemia.
Study patients showed reduced HbA1c and pre-prandial insulin requirements after transitioning to insulin glargine U300.
A retrospective study to assess phentermine and the OPTIFAST diet program on weight and diabetes outcomes at 6 months.
Findings from this review were consistent with other short-term studies that evaluated weight changes post-HAART initiation.
Once-weekly levothyroxine vs. daily levothyroxine proved safe and effective for the treatment of hypothyroidism in non-adherent young and middle-aged adults.
Synthroid was associated with an 11% lower likelihood of having TSH labs out of range when compared with similar patients taking generic levothyroxine.
After 3 months of treatment with vitamin D, the researchers found a significant increase in serum vitamin D as well as significant reductions in TSH to 4.7 and anti TPO titre.
Somatotropin (recombinant human growth hormone) in adults with growth hormone deficiency significantly raised HDL levels at 24 months.
A group of 26 patients with uncontrolled type 1 diabetes were randomly divided to either 1.8mg of liraglutide or placebo after fasting overnight.
Data results found that treatment with canagliflozin decreased serum levels of leptin and IL-6 compared to GLIM (26% reduction for leptin, 23% reduction for IL-6).
Treatment with iGlarLixi resulted in a lower rate of gastrointestinal (GI) adverse events vs. Lixi, according to findings from a post-hoc analysis.
The study evaluated adherence to topical testosterone therapy in a real-world cohort of commercially insured males with primary or secondary hypogonadism.
The analysis showed mean HbA1c was reduced in both treatment arms but was significantly lower in the canagliflozin arm vs. sitagliptin arm.
Results of this analysis found that patients treated with empagliflozin/linagliptin single-pill combination were more likely to reach and maintain an HbA1c target of ≤7% compared to patients treated with monotherapy.
This study describes three cases in which patients experienced hyperglycemia despite dose titration due to incorrect injection.
The case involves a 39-year old male patient who stated that he had an intentional 10-pound weight loss over a 2-month period after starting a dietary supplement that was a "fad" at his office.
A significant reduction was seen in the total daily dose for V-Go patients who had been previously administering ≥2 insulin injections per day.
In type 2 diabetic male patients, a low testosterone level was found to be associated with anemia. These findings are consistent with previous reports.
The study aimed at analyzing data obtained from randomized controlled trials (RCTs) to determine the safety and efficacy of glucagon like peptide-1 receptor agonists (GLP-1RA) in patients with T1DM.
This retrospective analysis demonstrated that early initiation of insulin is beneficial in patients with new onset T2DM.
The study authors reported that treatment with LIRA significantly improved all clinical parameters tested for patients with new onset T2DM.
When intravenous boluses of calcium gluconate failed to improve the patient's serum calcium levels, he was initiated on a continuous calcium gluconate infusion over 36 hours.
Upon presentation to the endocrine clinic for evaluation of his low serum cortisol, the patient complained of a 24-pound weight gain over a two-year period, feeling fatigued, as well as facial puffiness.